Varela and Brodsky (2013) stated that the severity of symptoms is variable among patients diagnosed with PNH and not all patients require treatment. Links to various non-Aetna sites are provided for your convenience only. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: Interim analysis of post-marketing surveillance. These researchers discussed recent advances in NMO diagnosis and treatment and the differential diagnosis in patients presenting with LETM. Two to 10 % die and 1/3 progress to end-stage renal failure at first episode. Aetna Inc. and its subsidiary companies are not responsible or liable for the content, accuracy, or privacy practices of linked sites, or for products or services described on these sites. These researchers described a patient presenting with severe preeclampsia/HELLP syndrome at 26 weeks gestation that was treated with eculizumab, which resulted in marked clinical improvement and complete normalization of laboratory parameters. Moreover, terminal complement inhibition does not prevent the development of chronic APSN. Blood. prevention of photoreceptors and retinal pigment epithelium loss (neuro-protection induction, oxidative damage prevention, and visual cycle modification), and, Clinically apparent distal embolization (e.g., lower extremity ulceration, tissue necrosis, gangrene, limb amputation or other end-organ damage). 2017;36(12):2859-2867. Evidence supporting the use of methotrexate and rituximab in MG has been published recently, in addition to conflicting randomized trials that were not successful, evaluating the use of tacrolimus as a steroid sparing agent. In a multi-center, retrospective study, Pecheron and associates (2018) studied 33 children from 15 centers treated with eculizumab for severe hemolytic uremic syndrome caused by Shiga toxin-producing E. coli (STEC-HUS). We use some essential cookies to make this website work. Fatal immune hemolytic anemia following allogeneic stem cell transplantation: Report of 2 cases and review of literature. Effect of complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. 2017;23(2):175-180. 1981;57(1):83â89. Pichon Riviere A, Augustovski F, Garcia Marti S, et al. Waltham, MA: UpToDate; reviewed July 2018. They included randomized controlled trials (RCTs) comparing eculizumab with placebo or best available therapy for patients with a confirmed diagnosis of PNH. 2008;13(9):993-1000. Eculizumab compared with placebo showed a greater proportion of patients with transfusion independence: 51% (22/43) versus 0% (0/44); risk ratio (RR) 46.02, 95% CI 2.88 to 735.53; P = 0.007; moderate quality of evidence; and withdrawal for any reason: 4.7% (2/43) versus 22.72% (10/44); RR 0.20, 95% CI 0.05 to 0.88; P = 0.03; moderate quality of evidence. 2010;25(10):2035-2045. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. 2005;106:3699â3709. Recurrent dense deposit disease after renal transplantation: An emerging role for complementary therapies. Blood. Lee JW, Jang JH, Kim JS, et al. Blood Rev. Huang and colleagues (2018) reported on a girl with systemic MAP who had severe CNS involvement and responded to eculizumab. Drug Des Devel Ther. Wei Y, Liao H, Ye J. Pediatr Nephrol. Horizon Scanning Technology Briefing. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. This case provided the first evidence that eculizumab may have a place in the management of crescentic dense deposit disease. The page could not be loaded. London New Drugs Group. Tobin WO, Weinshenker BG, Lucchinetti CF. Int J Hematol. Pediatr Transplant. Response rates to current therapies (mainly PE) are unsatisfactory. Molina has established Molina Clinical Policy that function as one of the sets of guidelines for coverage decisions or determinations. These are life-threatening genetic diseases that cause the breakdown of red blood cells resulting in various medical complications. Expanding the therapeutic options for renal involvement in lupus: Eculizumab, available evidence. In the absence of bleeding, her hematocrit (Hct) decreased to 10.2 %. Leeds, UK: Egton Medical Information Systems (EMIS); updated September 21, 2009. All patients showed a sustained improvement of renal function and normalization of complement parameters after treatment with eculizumab (median follow-up of 9 months [range of 1 to 17). The assessment noted that, "although some private insurance companies in the United States give coverage to certain patients, most health systems in different countries do not cover it due to its high costs and because it provides marginal benefits when compared with standard care for PNH.". Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. van Doorn (2009) noted that epidemiological studies have shown that the incidence of Guillain-Barre syndrome (GBS) remains stable at about 2/100,000 per year; but that there have been changes in hospitalization use, likely due to the widespread availability of intravenous immunoglobulin (IVIG). Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. To achieve and to sustain therapeutic eculizumab level greater than 99 µg/ml, CH50 should be less than 10 % of the lower limit of normal, corresponding to 0 to 3 CAE if using a standard enzyme immunoassay or 0 to 15 CH50 units if the Diamedix hemolytic assay is used. Bone marrow cellularity less than 25 percent (or cellularity 25 to 50 percent if less than 30 percent of residual cells are hematopoietic); Alexion Pharma UK Ltd. Form B: Detailed appraisal information, Soliris. N Engl J Med. A total of 30 eyes of 30 patients were enrolled; 18 fellow eyes also met inclusion criteria and were analyzed as a secondary end-point. Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition. Cochrane Database Syst Rev. Birmingham, UK: NHSC; 2006. Soliris must be diluted to a final admixture concentration of 5 mg/mL using the following steps: • Withdraw the required amount of Soliris from the vial into a sterile syringe. Kidney Int Rep. 2017;3(2):482-485. Eculizumab-treated patients had a significantly better early graft function, less arteriolar hyalinosis and chronic glomerulopathy on a protocol biopsies taken on day 30, 1 year, and 3 years after transplantation. Zareba KM. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: The 301 study. Common Drug Review. 2015;55(3):623-628. The authors stated that novel therapeutic strategies for LETM in the context of NMO include eculizumab, which could be considered in patients with active disease who have failed azathioprine and rituximab. Ottawa, ON: CADTH; February 19, 2010. The trial did not assess overall survival, transformation to myelodysplastic syndrome and acute myelogenous leukemia, or development or recurrence of aplastic anemia on treatment. Chanchlani R, Thorner P, Radhakrishnan S, et al. Kanakura Y, Ohyashiki K, Shichishima T, et al. This Drug Policy is provided for informational purposes. All Wales Medicines Strategy Group. Vivarelli M, Emma F. Treatment of C3 glomerulopathy with complement blockers. The authors identified one multicenter (34 sites) phase III RCT involving 87 participants. Le Quintrec M, Lapeyraque AL, Lionet A, et al. Moreover, in a review on advances in diagnosing and managing AMR, Jordan et al (2010) stated that newer approaches in treating AMR include bortezomib and eculizumab. Although nearly all patients reported at least one adverse event, discontinuation from treatment due to a nonfatal adverse event was seen in only five patients over the entire period of study. Whether the prevention or successful treatment of AMR will decrease the prevalence of chronic injury and improved long-term graft survival will require longer-term studies. Each member's benefit plan offers coverage for a wide range of healthcare services, and should be reviewed as the first step in determining coverage. Waltham, MA: UpToDate; reviewed August 2013. Hemolytic uremic syndrome is defined by the triad of mechanical hemolytic anemia, thrombocytopenia and renal impairment. Other novel complement-targeting agents should be investigated as potential therapeutic options for TA-TMA to reduce or even eliminate cost-limiting factors currently relevant to eculizumab therapy.Dhakal et al (2017) stated that TA-TMA is a rare entity with no standard of care and high mortality, despite the use of PE. Parker CH, Kar S, Kirkpatrick P. Eculizumab. For patients with severe, oliguric AMR, graft loss is inevitable without timely intervention. Before the introduction of eculizumab and treprostinil, no studies had reported an effective treatment of neurologic involvement in MAP, and surgical drainage had not been found to be effective for sub-dural effusion. Longitudinally extensive transverse myelitis. 2018;33(8):1277-1281. The authors did not observe any difference between intervention and placebo for the most frequent adverse events. Advances in diagnosing and managing antibody-mediated rejection. Soliris Medical Policy Prior Authorization Program Summary OBJECTIVE The intent of the Soliris medical drug criteria is to appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and to verify appropriate FDA labeled dosing for specified indications. Recently, several new mAbs reacting with CD20 have been developed. A systematic review of evidence for eculizumab by the Institute for Clinical Effectiveness and Health Policy (Pichon Riviere et al, 2011) concluded that "the available evidence shows that eculizumab is effective in reducing complement-mediated hemolysis", but that "the evidence is not very strong since there is no CRCT [controlled randomized clinical trials] conducted on prevention of thrombotic events." 2013;98(4):406-416. Eur J Haematol. 2012;75(1):71-76. de Fontbrune FS, Galambrun C, Sirvent A, et al. Treatment with eculizumab normalized proteinuria within 1, 2 and 7 months, respectively. A case report and systematic review. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. No 436/07. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. However, the combination treatment may entail a considerable economic burden on the patient and family. Neurology. Longitudinally extensive transverse myelitis is not pathognomonic of NMO, therefore it is important to investigate for other causes of myelopathy in these patients. Elevation of serum membrane attack complex before treatment may predict response. Currently, no specific treatment exists for STEC-HUS. Concurrent use of therapeutic plasma exchange (TPE) would remove eculizumab from the blood as well as replenish C5 available for activation, and supplemental doses would be required after each TPE session. 2009;373:759-767. These investigators searched the Cochrane Neuromuscular Disease Group Specialized Register (August 2011), the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 3 2011), MEDLINE (January 1966 to August 2011), EMBASE (January 1980 to August 2011) and clinicaltrials.gov (August 2011). Treating providers are solely responsible for medical advice and treatment of members. Eculizumab for dense deposit disease and C3 glomerulonephritis. By using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (scores can range from 0 to 100, with higher scores on the global health status and functioning scales indicating improvement), the trial showed improvement in health-related quality of life in patients treated with eculizumab (mean difference (MD) 19.4, 95% confidence interval [CI]: 8.25 to 30.55; P = 0.0007; low quality of evidence). Eculizumab was withdrawn due to multiple viral re-activations, but the re-introduction of the drug a few months later enabled a moderate decrease in proteinuria. Patient UK. Curr Opin Hematol. Some patients who present with only cutaneous symptoms at first may develop systemic symptoms several years later. In a Lancet review of eculizumab for PNH, Parker (2009) explained the eculizumab does not increase the risk of catastrophic hemolytic crisis if the drug is discontinued. The placebo group was infused with saline. Patients with GA measuring from 1.25 to 18 mm(2) based on spectral-domain optical coherence tomography (OCT) imaging were included in this study. Patients were randomized 2:1 to receive I.V. Int J Hematol. Curr Opin Organ Transplant. Pediatr Nephrol. These medical policies apply to our Georgia Medicaid plans. Blood. Lancet. 2015;99(9):1953-1959. de Holanda MI, Porto LC, Wagner T, et al. 2014;13(6):685-696. Pediatr Nephrol. Semin Thromb Hemost. Policies and guidelines Tools and resources Claims and billing Patient management Become a provider Contact us Provider News Center . Patient 4 was diagnosed with C3G at 9 years of age, with progression to end-stage renal disease (ESRD) within 2 years, followed by a first renal transplantation (R-Tx) with early disease recurrence and graft loss within 39 months. There was more chronic glomerulopathy in the splenectomy-alone and eculizumab-alone groups at 1 year, whereas splenectomy plus eculizumab patients had almost no transplant glomerulopathy. 2018;17(6):519-529. Dhakal P, Giri S, Pathak R, Bhatt VR. Oncologist. Stegall MD, Gloor JM. Kaabak M, Babenko N, Shapiro R, et al. U.S. Food and Drug Administration (FDA). At week 4, the proportion of the patients able to walk independently (functional grade less than or equal to 2) was 61 % (90 % CI: 42 to 78; n = 14) in the eculizumab group, and 45 % (20 to 73; n = 5) in the placebo group. Requirements for transfusion of red cells increased during pregnancy, from a mean of 0.14 units per month in the 6 months before pregnancy to 0.92 units per month during pregnancy. These are the guideline rates in effect from 2010. Occurrence at an extremely premature gestational age is most challenging as there are dichotomous imperatives: delivery as definitive therapy for maternal health versus prolongation of pregnancy to avoid prematurity and associated morbidities. The important role of B cells in the pathogenesis of autoimmune disorders has provided a strong rationale to target B cells in SLE. Complement targeting therapy (e.g., eculizumab) has recently emerged as a novel therapeutic option for patients with C3G. Sanders D, Wolfe G, Benatar M et al. Hillmen P, Young NS, Schubert J, et al. Blood. The authors conducted a comprehensive search strategy. Gupta S, Fenves A, Nance ST, et al. 2012;12(4):1046-1051. No deaths or meningococcal infections occurred. All patients, regardless of the presence of concomitant LN, presented with severe hypocomplementemia and renal function impairment. This small trial had high risk of bias in many domains (attrition and selective reporting). In 54% of pregnancies that progressed past the first trimester, the dose or the frequency of use of eculizumab had to be increased. Clin Exp Nephrol. 2011;26(4):621-624. Utilization Management Guidelines; Medical Policies. Silver Spring, MD: FDA; June 27, 2019. Brodsky RA. 2018;72(1):84-92. Edinburgh, Scotland: Alexion; November 9, 2007. No patients died during the study. Sciascia S, Radin M, Yazdany J, et al. Robak E, Robak T. Monoclonal antibodies in the treatment of systemic lupus erythematosus. The roles for bortezomib and eculizumab in the management of antibody mediated rejection remain to be defined. Canaud et al (2013) stated that thrombotic microangiopathy (TMA) is one of the hallmark vascular lesions of anti-phospholipid syndrome nephropathy (APSN). Blood. These medical polices apply to our Kentucky Marketplace plans. Transplantation. Curr Opin Organ Transplant. Blocking of these cytokines by mAbs can be also a successful therapy for patients with SLE. Adherence to these standards may lead to improved patient outcomes. There are 4 possible causes for this complication. Prior Authorization Guide Medical Policies (Medical Coverage Guidelines) We strive to cover procedures, treatments, devices and drugs proven to be safe and effective for a particular disease or condition and continually look at new medical advances and technology to determine for coverage and payment purposes if any is superior to those already in use. Maintenance Phase. This suggests trials of eculizumab in GBS should be considered. 2000;70: 327-34. Alexion Pharma UK Ltd. Soliris. Expert Opin Investig Drugs. Eculizumab treatment in severe pediatric STEC-HUS: A multicenter retrospective study. Scottish Medicines Consortium. Twenty cord-blood samples were examined for the presence of eculizumab; the drug was detected in 7 of the samples. 2017;17(1):46-55. 2013;9(11):1113-1124. Get information on manufacture pricing, what the guidelines and procedures are and help with billing issues. Last Review 11/11/2020. A Cochrane review (Marti-Carvajal et al, 2014) assessed the clinical benefits and harms of eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria (PNH). Copyright Aetna Inc. All rights reserved. Alexion Pharmaceuticals, Inc. Soliris (eculizumab). 2012;13(13):1873-1883. 2014;98(8):857-863. The high cost and need for repeated infusions have led to the search for other immune therapies, the efficacy of which had not yet been confirmed in RCTs. Canaud G, Kamar N, Anglicheau D, et al. At the time of TMA diagnosis, infections were present in 50 % of the patients and acute graft-versus-host disease (GVHD) in 33 %. Soliris is used to prevent the breakdown of red blood cells in adults with paroxysmal nocturnal hemoglobinuria (PNH). Am J Hematol. The authors concluded that clinical and histopathologic data suggest a response to eculizumab in some but not all subjects with dense deposit disease and C3 glomerulonephritis. However, more than 1,000 aHUS patients investigated for complement abnormalities have been reported. 2007;110(12);4123-4128. Cytometry B Clin Cytom. New mAbs directed against CD20 include fully human mAb ofatumumab, which has a greater than 90 % humanized framework and GA-101, a novel third-generation fully humanized and optimized mAb. The possibility that anaphylaxis and intra-cranial abscess were related to eculizumab could not be excluded. The authors concluded that eculizumab was associated with better early graft function and improved graft morphology; however, there was an unacceptably high number of early graft losses among the eculizumab-treated children. Transplant Rev (Orlando). Drugs Today (Barc). Hill A, Hillmen P, Richards SJ, et al: Sustained response and longâterm safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Selective therapeutic depletion of B-cells became possible with the availability of the anti-CD20 antibody rituximab and anti-CD22 antibody epratuzumab. The authors concluded that within the limits of this retrospective analysis, this study demonstrated that eculizumab use may result in high response rate and 1-year survival in patients with TA-TMA refractory to discontinuation of calcineurin inhibitor and PE. In the first 3 weeks after transplantation (median = 6 days), 24 patients developed sudden onset oliguria and rapidly rising serum creatinine with marked rebound of donor-specific antibody, and a biopsy that showed features of AMR. Immunosuppressants were associated with significant side effects. At a median follow-up of 533 days, 4 of 14 splenectomy-alone patients experienced graft loss (median = 320 days), compared to 4 of 5 eculizumab-alone patients with graft failure (median = 95 days). A total of 6 subjects with dense deposit disease or C3 glomerulonephritis were treated with eculizumab every other week for 1 year. These medical policies apply to our Indiana Medicaid plans. Parker (2009) reported, however, that 16 patients have discontinued treatment with eculizumab without having exacerbation of hemolysis. Subjects underwent biopsy before enrollment and repeat biopsy at the 1-year mark. In the eculizumab group, 4 non-vaccinated children lost their grafts during the course of a flu-like infection. Dmytrijuk A, Robie-Suh K, Cohen MH, et al. News Release. Haematologica. Walsh and Johnson (2019) noted that HUS remains a leading cause of pediatric AKI. In a subgroup of patients, however, rapid neurological improvement was described. Atypical hemolytic uremic syndrome. 2014;371(15):1459-1461. Lancet Neurol. Patients were treated with eculizumab according to the aHUS therapeutic scheme. Rheumatol Int. He noted that, of 195 patients in clinical trials, 16 had discontinued treatment with no catastrophic hemolysis reported. Most patients (55 %) did not benefit from eculizumab and renal dysfunction as well as neurological sequelae did not resolve. 2013;90(1):16â24. Maintenance immunosuppression was based on a combination of low-dose tacrolimus and mycophenolate, without steroids. Ten hemorrhagic events and 2 thrombotic events were documented; both thrombotic events occurred during the postpartum period. Pittock SJ, Berthele A, Fujihara K, et al. Under this definition are now included membrano-proliferative glomerulonephritis type II (dense deposit disease) and C3 glomerulonephritis. These investigators reviewed pharmacologic treatment options for TA-TMA. Moreover, they stated that further prospective studies in a larger patient cohort are needed to better understand the long-term clinical implications of eculizumab treatment in pediatric patients with immune complex-mediated MPGN, with a special emphasis on determining the optimal duration of treatment. Humana’s medical and pharmacy coverage policies are based on evidence published in peer-reviewed medical literature, technology assessments obtained from independent medical research organizations, evidence-based consensus statements, and evidence-based guidelines from nationally recognized professional healthcare organizations. Guinan EC. Lebreton and colleagues (2017) reported on 4 pediatric cases of C3 glomerulopathy treated with eculizumab. At least 51% of GPI-anchored protein deficient poly-morphonuclear cells; Anti-acetylcholine receptor (AchR) antibody positive; Myasthenia Gravis Foundation of America (MGFA) clinical classification II to IV; MG activities of daily living (MG-ADL) total score greater than or equal to 6; Anti-aquaporin-4 (AQP4) antibody positive; Member exhibits one of the following core clinical characteristics of NMOSD: Area postrema syndrome (episode of otherwise unexplained hiccups or nausea and vomiting); Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions; Symptomatic cerebral syndrome with NMOSD-typical brain lesions; There is no evidence of unacceptable toxicity or disease progression while on the current regimen; The member demonstrates a positive response to therapy (e.g., reduction in number of relapses); Anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis, C3 glomerulopathy/glomerulonephritis/nephropathy, Immune complex-mediated membranoproliferative glomerulonephritis, Inflammatory myositis (e.g., dermatomyositis and polymyositis), Ischemia-reperfusion injury in kidney transplantation, Preeclampsia with hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome, Prevention of intravascular hemolysis due to red blood cell alloantibodies, Shiga toxin E. coli-related hemolytic uremic syndrome (STEC-HUS), Stem cell transplant-associated thrombotic microangiopathy, Thrombotic thrombocytopenic purpura (TTP), 600 mg IV every weekly for the first 4 weeks, followed by, 900 mg IV for the fifth dose 1 week later, then, 900 mg every weekly for the first 4 weeks, followed by, 1200 mg for the fifth dose 1 week later, then, 900 mg weekly for the first 4 weeks, followed by, 1200 mg for the fifth dose 1 week later, then, Paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, Atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, Generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody positive, Neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive, no criteria for Stx-HUS (stool culture and polymerase chain reaction for Stx; serology for anti-lipopolysaccharides antibodies), and. 2005;106(7):2559â2565. (Soliris - Alexion Pharmaceuticals, Inc.). 2018;33(8):1385-1394. 2011;6(1):60. Scheiring J, Rosales A, Zimmerhackl LB. Laboratory tests for paroxysmal nocturnal hemoglobinuria (PNH). Handy tools and resources for members ... Download guidelines that outline generally accepted minimum standards of care. Bone marrow failure syndromes: Paroxysmal nocturnal hemoglobinuria. Autoimmun Rev. In participants without a classical rash of dermatomyositis, inclusion body myositis should have been excluded by muscle biopsy. In an open-label, proof of concept efficacy and safety study, Bomback et al (2012) examined the effects of eculizumab for dense deposit disease and C3 glomerulonephritis. Elevated serum membrane attack complex levels normalized on therapy and paralleled improvements in creatinine and proteinuria. Guideline figures for carrying out a summary assessment of court costs, listed by pay band and grade for different parts of the country. San Francisco, CA: Epocrates; 2019. Huang YC, Wang JD, Lee FY, Fu LS. While the kidney is most commonly affected, TA-TMA involving organs such as the lung, bowel, heart, and brain is now known to have specific clinical presentations. Curr Drug Targets. Specifically, TA-TMA can manifest as a multi-system disease occurring after various triggers of small vessel endothelial injury, leading to subsequent tissue damage in different organs. FDA News. Find out previous guideline rates for 1999–2009. PNH results in anaemia (low red blood cell counts), thrombosis (blood clots in the blood vessels), pancytopenia (low counts of blood cells) and dark urine, while aHUS … Routine review; no change to coverage guidelines The assessment stated that "it has not been determined if eculizumab therapy increases survival of PNH patients yet." Jaretzki A, Barohn RJ, Ernstoff RM et al. This case demonstrated several noteworthy features including hyperhemolysis in a patient without a Hb disorder, the development of an antibody to an unknown RBC antigen, and the failure of eculizumab to prevent intravascular hemolysis after transfusion. Also, a repeat renal biopsy after eculizumab therapy to document changes in the histopathology after therapy was not available. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. In addition, some therapies, including corticosteroids and plasma exchange, are not only ineffective, but have been associated with clinical worsening. This policy supports medical necessity review of eculizumab (Soliris ®) and ravulizumab (Ultomiris™). Brodsky RA, Young NS, Antonioli E, et al. A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS 13) level was always greater than 10 %. Eculizumab (Soliris). These investigators noted that the natural history of acute AMR after positive cross-match kidney transplantation involves an acute rise in donor-specific alloantibody in the first few weeks following transplantation. An UpToDate review on âInvestigational immunosuppressive drugs and approaches in clinical kidney transplantationâ (Vella, 2013) states that âAgents currently under development include eculizumab, alefacept, voclosporine, sotrastaurin, tasocitinib, and bortezomib. Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy. Moreover, they stated that prospective trials are needed to confirm these results.Jodele et al (2015) stated that hematopoietic stem cell transplantation (HSCT)-associated thrombotic microangiopathy (TA-TMA) is now a well-recognized and potentially severe complication of HSCT that carries a high risk of death. Modifiers of complement activation for prevention of antibody-mediated injury to allografts. Surrey, UK: Alexion; revised May 2009. Lee JW, Sicre de Fontbrune F, Wong LL, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: The COMPLETE study. Statement of Adivice. The 4th study comparing pulsed oral dexamethasone with daily oral prednisolone and found that the dexamethasone regime had a shorter median time to relapse but fewer side effects. 2015;29(3):191-204. But the drug doesn't come cheap, with a potential price tag of £340,000 per patient. Vale of Glamorgan, UK: All Wales Medicines Strategy Group; April 29, 2009. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Eculizumab in atypical hemolytic uremic syndrome: Long-term clinical course and histological findings. 2013;121(25):4985-4996. Deciphering antibody-mediated rejection: New insights into mechanisms and treatment. Moreover, they noted that thorough investigation of patients with LETM who are negative for NMO-IgG may lead to an alternate cause for myelopathy. • Maintenance phase: 900 mg of Soliris administered via a 25 – 45 minute (35 minutes ± 10 minutes) These researchers conducted a literature search developed a priori, to identify articles reporting clinical experience with the use of eculizumab in SLE patients, focusing on renal involvement. Eculizumab. During treatment with eculizumab, the percentage of PNH erythrocytes in peripheral blood increases because eculizumab enhances survival of the abnormal cells by protecting them against complement-mediated lysis. The authors concluded that response rate and OS after eculizumab in this cohort compared favorably with previously published data in TMA after allogeneic HSCT. We also use cookies set by other sites to help us deliver content from their services.